MEDIASTINAL LARGE-CELL LYMPHOMA WITH SCLEROSIS REFRACTORY TO CONVENTIONAL CHEMOTHERAPY CAN RESPOND AFTER DAILY ORAL CYCLOPHOSPHAMIDE

Mediastinal large-cell lymphoma with sclerosis (MLCLS) is a distinctiv e subtype of non-Hodgkin's lymphoma (NHL) with unique clinicopathology aspects and aggressive behavior. Prompt diagnosis and aggressive chem otherapy followed by consolidation radiotherapy may result in long-ter m survival in the majority of cases. However, a subset of patients do not respond to first-line or salvage treatment and have a poor prognos is. We report here a 27-year-old man with MLCLS resistant to several c onventional chemotherapies and to radiotherapy who achieved a very goo d partial remission after one year's treatment with daily oral cycloph osphamide (100 mg/day). This is the first report of refractory MLCLS w ith good response to daily oral cyclophosphamide. This case suggests t hat daily oral monochemotherapy might be benefical for some patients w ith mediastinal large-cell lymphoma with sclerosis refractory to conve ntional intravenous chemotherapies and radiotherapy.